Tampere University Hospital Tampere Heart Centre
Tampere, Pirkanmaa, 33100, Finland
Location status: Recruiting
NCT Number: NCT06804499
The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).
The main questions it aims to answer are:
Are we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years?
Participants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects.
Medical healthcare records are used to follow all study subjects, and no follow-up visits are required.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Tampere, Pirkanmaa, 33100, Finland
Location status: Recruiting
Source data verification is not planned for the baseline data acquisition. SCD data is collected from the national death certificate register, which is mandated by Finnish legislation. Death certificates must include information about all the significant prevalent diseases and the events and circumstances leading to death. Also, data regarding the cause of death (ICD-10 classification) and the place of death must be included. The certificate is written by the last physician treating the patient and is complemented with medical or medicolegal autopsy results if available. Research members will fully review all detected SCD case from medical records and death certificates.
Patients treated for CAD in Tampere Heart Hospital are recruited by research staff according to up-to-date Standard Operating Procedures (SOP). Research staff will conduct surveys and physiological measurements and take a blood sample in as planned. The blood sample is processed and stored according to research plan. The collected data is entered and saved to the Tampere Heart Hospital RedCap database. All research staff is trained according to up-to-date SOP. The final analytics of the blood samples including genetic testing will be decided later.
The study is designed to have 80% power (alpha 0.05) to demonstrate a small-medium effect (Cohen's D 0.2-0.5) for normally distributed variables. To this end, 150-200 SCD cases should be detected in the follow-up. Based on previous research, 4000 subjects with four years of follow-up need to be recruited to fulfil the target number of SCD cases. With this sample, a 2.5-3.5 times risk ratio for categorical variables could be detected (80% power).
Missing data will be addressed as such. If significant number of study subjects with missing data will be detected data imputing can be considered during analysis.
Prospective data regarding SCD will be analyzed in addition to conventional statistical methods, with Cox regression model. Also Fine Gray subdistribution models will be used. Machine learning model can used especially analyzing ECG and genetic data.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subgroup with blood samples:
Blood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time>110ms in the latest ECG.
Time frame: 15 years
The primary endpoints of the study are sudden cardiac death (SCD) and sudden cardiac arrest (SCA).
A SCD is defined as:
A SCA is defined as:
Time frame: 15 years
Secondary endpoint include significant cardiovascular diseases, like detected strokes, myocardial infarctions, revascularization procedures, arrythmias (eg atrial fibrillation).
Time frame: 15 years
Secondary endpoints include significant cardiovascular diseases, like detected strokes, myocardial infarctions, revascularization procedures, and arrhythmia (e.g. atrial fibrillation). Treatment compliance is monitored based on drug purchases and achieving clinically set secondary prevention targets (e.g., cholesterol levels, blood pressure, and blood glucose levels).
Contact information is provided by the study sponsor or research team.
Juho Tynkkynen, Medical Doctor, Phd
CONTACT
Jussi Hernesniemi, Professor
CONTACT
Tampere Heart Hospital
Other
Acronym: CADSCA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07444931
Arterial Occlusive Diseases, Arteriosclerosis
Hadera, Israel
View Trial DetailsNCT03049254
Arrhythmias, Cardiac, Arrhythmogenic Right Ventricular Cardiomyopathy
Rochester, Minnesota, United States
View Trial DetailsNCT06642168
Cardiovascular Diseases, Death
Paris, France
View Trial DetailsNCT06447805
Arrhythmias, Cardiac, Cardiac Arrest
Halmstad, Halland County, Sweden
View Trial Details